Traws Pharma reports financial results for the second quarter of 2024, provides recent business highlights

Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent $14 million private placement (cash runway to support planned operations through year-end), with recently achieved clinical milestones, puts Traws on track to deliver significant clinical pipeline results in H2 2024 and beyond

• Leading antiviral program, tivoxavir marboxil, for influenza, including avian influenza, doses first cohort in Phase 1 dose extension study in Australia
• COVID-19 program, ratutrelvir, has completed single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1 study in Australia
• The oncology strategy includes investigator-sponsored studies (ISTs), planned to begin in the second half of 2024, which add a new dimension to the narazaciclib program, with continued investigator support for rigosertib
• Company Update Call Scheduled for August 15, 2024 at 8:00 a.m. ET

NEWTOWN, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical-stage biopharmaceutical company developing oral small molecules for viral respiratory diseases and cancer, today outlined recent business highlights and reported unaudited financial results for the second quarter ended June 30, 2024. The Company plans to hold a conference call and live webcast on Thursday, August 15, 2024 at 8:00 a.m. ET.